All In Biotech

Drug Trial Radar · NCT02503774

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

192

Actual

Start

Jul 24, 2015

Primary completion

Jan 22, 2021

Study completion Mar 7, 2023

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 21, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 101 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Participants with Select Advanced Solid Tumors

Conditions

  • Solid Tumors

Interventions

  • OleclumabDrug

    Participants will receive IV infusion of oleclumab as stated in arms' description.

  • DurvalumabDrug

    Participants will receive IV infusion of durvalumab as stated in arms' description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting Toxicities (DLTs) in Dose-escalation PhaseTime frame: From Day 1 to Day 28 after first dose of study drug
  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: From Day 1 through 200.1 weeks (corresponding to maximum observed duration)
  3. Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEsTime frame: From Day 1 through 200.1 weeks (corresponding to maximum observed duration)
  4. Number of Participants With Abnormal Vital Signs Reported as TEAEsTime frame: From Day 1 through 188.1 weeks (corresponding to maximum observed duration)
  5. Number of Participants With Change From Baseline in QTcFTime frame: Baseline (prior to Day 1 dose) through 188.1 weeks (corresponding to maximum observed duration)

Locations

18 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    La Jolla, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Gainesville, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    St Louis, Missouri

  • Research Site

    Durham, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Nashville, Tennessee

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Camperdown, Australia

  • Research Site

    Parkville, Australia

  • Research Site

    St Leonards, Australia

  • Research Site

    Woolloongabba, Australia

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.